INTRODUCTION
The observation that arachidonic acid, a prostaglandin precursor, induces platelet aggregation and the platelet release reaction (1) initiated several investigations to elucidate the biochemical nature of these phenomena. It was found that prostaglandin endoperoxides (PGG2 and PGH,)1 are potent inducers of platelet aggregation (2) and that they accumulate transiently during the incubation of arachidonic acid with platelet-rich plasma (3) . Arachidonic acid-induced platelet aggregation, the platelet release reaction, and prostaglandin endoperoxide formation can all be prevented by the prostaglandin synthetase inhibitors aspirin and indomethacin, while endoperoxide-induced platelet aggregation cannot. In recent studies using washed human platelets resuspended in a physiological salt solution, it was shown that either arachidonic acid or PGG2 is converted within 30 s into thromboxane A2, a highly unstable intermediate with a t-at 370C tonin from platelets pretreated with indomethacin. Previously, we had reported in a preliminary communication (5) that when arachidonic acid is incubated with platelets in the presence of plasma, the releaseinducing activity that develops is maximal at 3 min and still present in appreciable amounts after 10 min. We now present evidence that this releaseinducing activity is thromboxane A2 METHODS Platelet preparations. Human blood was collected from volunteers, who denied having taken any drug within the previous week, into 0.05 vol of 0.1 M EDTA (pH 7.4) or 0.1 vol 3.8% trisodium citrate. Platelet-rich plasma (PRP) was obtained by centrifugation at 250 g for 15 min at 20-22°C. A part of the EDTA-PRP was further centrifuged at 1,000 g for 20 min to prepare platelet-poor plasma (PPP). The platelets sedimented in this manner were resuspended with a siliconized Pasteur pipette in either one-half or one-sixth vol of either PPP or a buffered saline solution (134 mM NaCl, 5 mM D-glucose, 15 mM Tris-HCl, pH 7.4). Platelet content was determined in a Coulter counter (Coulter Electronics Inc., Hialeah, Fla.).
Release of 5-hydroxytryptamine. A portion of the PRP under study was incubated at 37°C for 15 min with [3-14C]5-hydroxytryptamine creatinine sulphate, sp act 57 mCi/mmol (Amersham/Searle Corp., Arlington Heights, Ill.) at a final concentration of 0.5 ,uM and either aspirin (1 mM) or indomethacin (10 ,uM A portion of nonradioactive PRP, adjusted to contain about 109 platelets/ml by resuspension in 0.5 vol of plasma, was incubated at 37°C for different times with 1 mM arachidonic acid. Samples of 0.5 ml were transferred to and mixed with the PRP in the Eppendorf tubes, and incubation was continued at ambient temperature for 5 min. The sam- 2 We confirmed that these drugs do not inhibit the uptake of 5-hydroxytryptamine by platelets, and more than 90% of the radioactivity was incorporated into the platelets under these conditions. Less than 1% release of radioactivity from the platelets occurred after the direct addition of 1 mM arachidonic acid (99% pure, Nucheck Prep., Inc. Elysian, Minn.). ples were centrifuged for 1 min at 15,000 g, and 0. This mixed system of aspirin-inhibited and untreated platelets for studying substances responsible for intracellular communication causing release and aggregation was introduced by White and Witkop (6) .
Measurements of PGG2, PGH2, and thromboxane A2. For the measurement of prostaglandin endoperoxides (PGG2 and PGH2), nonradioactive PRP containing about 1 x 109 platelets/ml was incubated at 37°C for different times with 1 mM arachidonic acid, and duplicate tubes were decanted into either 10 ml ethanol or 10 ml ethanol containing 50 mg stannous chloride. Prostaglandin F21, was extracted, purified by column chromatography, and determined by radioimmunoassay as described previously (3) . The difference in values of PGF2a between reduced and unreduced samples was taken to be equivalent to the amount of endoperoxides. The amounts of PGF2o, in unreduced samples increased as a function of time to a maximum of 10 pmol/ml.
Since previous experiments (7) had demonstrated that plasma diminishes the oxygenation of archidonic acid by platelets, thromboxane A2 determinations were performed with platelet suspensions adjusted to contain about 3 x 109 platelets/ml by resuspension in one-sixth vol of either buffered saline or PPP as described above. Thromboxane A2 formation from arachidonic acid catalyzed by platelets resuspended in saline was determined as described elsewhere (4) .
For the determination of thromboxane A2 formed in plasma, 1-ml samples were incubated at 37°C for different times with 1 mM arachidonic acid containing 1 ,uCi [1-_4C]-arachidonic acid (Applied Science Labs, Inc., State College, Pa.). The samples were decanted into 5 ml methanol containing 25 mg stannouis chloride and diltuted with 4 ml saline. The stannous ion was precipitated by the addition of 1 M sodium hydroxide to pH 7, 0.1 ml formic acid was added, and the samples were extracted three times with 10 ml chloroform. The extracts were taken to dryness and applied to a silicic acid column (0.5 g). A fraction eluted with 10 ml chloroform was discarded, while a 12-ml fraction eluted with chloroform:methanol (95:5) was collected It was possible that the release-inducing substance was a prostaglandin endoperoxide generated from arachidonic acid. Therefore, the amotunt of endoperoxide present at different times after addition of arachidonic acid to PRP was determined simultaneously with measurements of release-inducing activity (Fig. 1) . Maximal amounts of the prostaglandin endoperoxides were present at 1 min as reported previously (3), and they were no longer detectable at 10 min. The substance was therefore dissociated from prostaglandin endoperoxides.
The time-couirse of appearance and disappearance of the release-inducing stubstance was similar witl either EDTA-PRP or citrated PRP. However, wheni platelets in btuffered saline soluition were incubated with arachidonic acid, the activity appeared and disappeared very rapidly. Under these conditions, maximal amouints of the activity were present between 10 and 60 s, depending on the final concentration of the added arachidonic acid (1-0.01 nM). This difference between washed platelets and PRP in the response to arachidonic acid was not duie to physical manipulation of the platelets, since they could be resuspended in plasma with restoration of the original time-course. Plasma could not be replaced by albumin or Cohn fractions I, II, III, IV-1, IV-4, IV-6, V, or VI, but could be replaced by serum.
The release-indtucing stubstance was released from the platelets, since almost identical time-couirses of 5-hydroxytryptamine release were obtained when incubates ofarachidonic acid and EDTA-PRP were either transferred directly to labeled PRP or rapidly centrifuged (15,000 g, 15 s) and the supematant transferred. The release-inducing activity of the supernatant remained essentially unchanged when kept at 0°C for 30 min but declined by about half when kept at 370C for 5 min.
In view of the similarity of our studies using platelets in buffered saline to those recently reported by Hamberg and co-workers (4), who used a similar system and detected the presence of thromboxane A2, it seemed possible that the release-inducing substance that peaked in plasma at 3 min was in fact thromboxane A2. To determine if this was the case, radioactive arachidonic acid was incubated for different times with platelets resuspended either in saline or in plasma. The radioactive products were extracted and chromatographed as described in Methods. Two radioactive derivatives that were less polar than thromboxane B2 (Rf values = 0.13, 0.18, and 0.04, respectively) and appear to be identical to the methanolic derivatives ofthromboxane A2 previously described (4) were detected. If the incubations were terminated by decanting into saline rather than methanolic stannous chloride before extraction and chromatography, the radioactivity in the thromboxane B2 zone was greatly increased, and that in the zone corresponding to the methanolic derivatives was greatly decreased. The time-courses of appearance and disappearance of these substances and thromboxane B2 in saline and plasma are shown in Figs. 2 and 3 , respectively. Indomethacin (20 ,M) added to PRP after 3 min of incubation with arachidonic acid caused no change in the time-course shown in Fig. 3 .
When platelets were sedimented from plasma 3 min after addition of radioactive arachidonic acid and the plasma was maintained at 37°C, the half-life of thromboxane A2-like material was estimated to be between 5 and 6 min. The half-life at room temperature was about 20 min. To demonstrate that thromboxane A2 was still available to be converted into thromboxane B2, the plasma was maintained at 370 for 10 min and then samples were decanted into either methanolic stannous chloride or saline. Treatment with saline resulted in an increase in thromboxane B2 from 8.8 to 14.6 uM and a decrease in the methanolic derivatives from 5.2 to 1.2 ,uM. Similar results were obtained when 20 ,uM indomethacin was added to the PRP before sedimentation of the platelets.
DISCUSSION
Since aspirin and indomethacin inhibit both platelet aggregation and the platelet release reaction induced by arachidonic acid, it is apparent that these phenom- ena depend on prostaglandin biosynthesis. The discovery that prostaglandin endoperoxides can induce aggregation (2) and the finding that these endoperoxides are rapidly and almost entirely metabolized by platelets to nonprostanoate compounds (8) suggested that PGG2 might be the active mediator of both aggregation and release. Thus, PGG2 was hypothesized to induce the release of ADP, which resulted in platelet aggregation (9) . On the other hand, other evidence indicated that arachidonic acid-induced aggregation and the release reaction could be dissociated. For example, arachidonic acid was found to aggregate storage-pool deficient and thrombin-degranulated platelets (10) that have little or no releasable ADP.
It occurred to us that endoperoxide-induced platelet aggregation and the release reaction might be separate phenomena resulting from the action of different mediators. We therefore devised a system to test this hypothesis and found that when prostaglandin endoperoxides were no longer detectable in mixtures of arachidonic acid and PRP, release-inducing activity was still present (5) . This activity was present in maximal amounts at 3 min and still present at 10 min (Fig. 1) .
The results we obtained with washed platelets were similar to those recently described by Hamberg and co-workers (4). They found that aggregation of indomethacin-treated platelets caused by mixtures of arachidonic acid or PGG2 and washed platelets resuspended in aqueous medium was greater than could be accounted for by PGG2 alone. They also reported that when arachidonic acid was incubated with washed platelets, a substance that released radioactivity from indomethacin-treated platelets labeled with [114C] serotonin was present at 30 s but not at 3 min.
In sophisticated experiments, they demonstrated that PGG2 is converted by platelets into thromboxane A2, an unstable intermediate rapidly attacked by hydroxyl groups in aqueous medium to yield thromboxane B2 (8-(1-hydroxy-3-oxopropyl)-9, 12L-dihydroxy-5, 10-hepatadecadienoic acid). The aggregating and release-inducing substances that they had detected had the same ti as thromboxane A2 and it was proposed that they are identical to thromboxane A2.
Thromboxane A2 is converted into the two epimers of mono-O-methyl-thromboxane B2 by treatment with methanol (4). We took advantage of this property to characterize it and followed the conversion of radioactive arachidonic acid into thromboxane A2 and B2 by thin layer chromatography. We confirmed that, in a washed platelet system, thromboxane A2-like material is present in maximal amounts before 30 s and barely detectable at 3 min (Fig. 2) . Little production of thromboxane B2 occurred after 1 min. By contrast, in PRP we found that the production of thromboxane B2 continued for at least 7 min, while the production of thromboxane A2-like material continued for at least 3 min (Fig. 3) . After 3 min the concentration of this material diminished in parallel with loss of the releaseinducing activity.
The present study indicates that plasma markedly prolongs the persistence of thromboxane A2 produced by platelets from arachidonic acid. One reason for this increased persistence is that plasma diminishes the oxygenation of arachidonic acid by platelets and this is associated with a more prolonged production of oxygenated prodtucts. However, material convertible into the methanolic derivatives of thromboxane A2 (or into thromboxane B2 by treatment with water) had a half-life of between 5 and 6 min in platelet-free plasma at 37°C, suggesting that plasma also stabilizes thromboxane A2. This is in direct contrast to our recent findings that plasma accelerates the rearrangement of PGH2 (11) . The persistence of thromboxane A2-like material in plasma dissociates it from PGG2 and associates it with persistent release-inducing activity. The nature of the factor in plasma that appears to stabilize thromboxane A2 has yet to be determined.
